文献速递炎症性肠病

支持监测炎症性肠病患者维多珠单抗谷浓度的证据

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-04-25

该回顾性队列研究纳入比利时鲁汶大学医院2015年9月1日至2016年10月1日开始维多珠单抗治疗的179例连续患者(溃疡性结肠炎66例,克罗恩病113例),发现第2周谷浓度>30.0 μg/mL、第6周>24.0 μg/mL及维持治疗期间>14.0 μg/mL与更高疗效终点达成概率相关(P < .05),高体重和更严重疾病与较低谷浓度及较低黏膜愈合概率相关(P < .05)。

要点

  • 第2周谷浓度>30.0 μg/mL、第6周>24.0 μg/mL、维持期>14.0 μg/mL与更高疗效达成概率相关(P < .05)。
  • 基线高体重及更严重疾病(高C反应蛋白和低白蛋白和/或血红蛋白)与30周内较低谷浓度及较低黏膜愈合概率相关(P < .05)。
  • 溃疡性结肠炎患者黏膜愈合率显著高于克罗恩病患者,但溃疡性结肠炎诊断并非较高谷浓度的独立预测因素。

核心结论

  • 在179例克罗恩病或溃疡性结肠炎患者的回顾性研究中,观察到维多珠单抗暴露与应答之间存在相关性。
  • 这些发现支持监测维多珠单抗谷浓度以预测患者结局。

研究设计与样本

  • 回顾性队列研究,纳入比利时鲁汶大学医院2015年9月1日至2016年10月1日开始维多珠单抗治疗的179例连续患者(溃疡性结肠炎66例,克罗恩病113例)。
  • 在所有输注前至第30周测量维多珠单抗血清浓度。
  • 疗效终点包括内镜下愈合(溃疡性结肠炎:Mayo内镜亚评分≤1;克罗恩病:无溃疡)、临床应答(医师整体评估)及生物学应答或缓解(基于C反应蛋白水平),分别在第14周(溃疡性结肠炎患者)和第22周(克罗恩病患者)评估。
  • 采用逐步向前纳入-向后剔除建模方法识别与维多珠单抗暴露和应答独立相关的因素。

主要发现

  • 第2周谷浓度>30.0 μg/mL、第6周>24.0 μg/mL及维持治疗期间>14.0 μg/mL与溃疡性结肠炎或克罗恩病患者更高疗效终点达成概率相关(P < .05)。
  • 基线较高体重和更严重疾病(基于高C反应蛋白水平及低白蛋白和/或血红蛋白水平)与30周内较低维多珠单抗谷浓度及较低黏膜愈合达成概率相关(P < .05)。
  • 溃疡性结肠炎患者黏膜愈合率显著高于克罗恩病患者,但溃疡性结肠炎诊断并非较高维多珠单抗谷浓度的独立预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Trough concentrations of vedolizumab were found to correlate with clinical response in phase 3 studies of patients with ulcerative colitis (UC) or Crohn's disease (CD). Nevertheless, there are no solid data to support monitoring of vedolizumab trough concentrations in treated patients. We investigated the correlation between vedolizumab exposure and response in a real-world population and aimed to identify patient factors that affect exposure and response. METHODS: We performed a retrospective cohort study of 179 consecutive patients (66 with UC and 113 with CD) who began vedolizumab therapy from September 1, 2015, through October 1, 2016, at University Hospitals Leuven, Belgium. Serum concentrations of vedolizumab were measured before all infusions up to week 30. Effectiveness endpoints included endoscopic healing (UC, Mayo endoscopic sub-score ≤1; CD, absence of ulcers), clinical response (physicians' global assessment), and biologic response or remission (based on level of C-reactive protein) and were assessed at week 14 (for patients with UC) and week 22 (for patients with CD). A stepwise forward addition-backward elimination modeling approach was performed to identify factors independently associated with vedolizumab exposure and response. RESULTS: Vedolizumab trough concentrations >30.0 μg/mL at week 2, >24.0 μg/mL at week 6, and >14.0 μg/mL during maintenance therapy associated with a higher probability of attaining the effectiveness endpoints for patients with UC or CD (P < .05). Higher body mass and more severe disease (based on high level of C-reactive protein and low level of albumin and/or hemoglobin) at the start of vedolizumab therapy associated with lower trough concentrations of vedolizumab over the 30-week period and a lower probability of achieving mucosal healing (P < .05). Mucosal healing was achieved in significantly more patients with UC than patients with CD, even though a diagnosis of UC was not an independent predictor of higher vedolizumab trough concentrations. CONCLUSIONS: In a retrospective study of 179 patients with CD or UC, we observed a correlation between vedolizumab exposure and response. These findings support monitoring of vedolizumab trough concentrations to predict patients' outcome.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Dreesen E, Verstockt B, Bian S, et al. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018. PMID: 29704680. doi:10.1016/j.cgh.2018.04.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。